Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19958804 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL3604748 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL5848851 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL3592625 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL3612669 | 1.00 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL2688839 | 0.95 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL2688835 | 0.95 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL15356409 | 0.88 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL7851601 | 0.85 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL22036328 | 0.85 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-4025256-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HSD17B10 4645/4885SMN1; SMN2 4221/4885NPC1 1331/4885 |
| US-20220257787-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HSD17B10 4645/4885SMN1; SMN2 4221/4885NPC1 1331/4885 |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | HSD17B10 4645/4885SMN1; SMN2 4221/4885NPC1 1331/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | HSD17B10 417/4885SMN1; SMN2 4057/4885NPC1 3378/4885 |
| US-11510992-B1 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | HSD17B10 4645/4885SMN1; SMN2 4221/4885NPC1 1331/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | HSD17B10 4780/4885SMN1; SMN2 1799/4885NPC1 2956/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | HSD17B10 4784/4885SMN1; SMN2 2235/4885NPC1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.